Using Nutrition to Support GLP-1 and Dual Incretin Treatments for Obesity: Practical Guidance for Diet, Managing Side Effects, and Keeping Weight Off

Central appetite modulation is a defining feature of incretin-based therapies. GLP-1 receptors located in the hypothalamus, brainstem, and reward-related regions of the central nervous system contribute to enhanced satiety, reduced hunger signaling, and diminished hedonic drive to eat [41,42]. Neuroimaging and behavioral studies demonstrate reduced activation of reward pathways in response to highly palatable foods during GLP-1 receptor agonist therapy, accompanied by decreased energy intake and altered food preferences [43]. A review on this topic presented that clinical trials consistently show substantial spontaneous caloric reduction, with average energy intake decreases ranging from approximately 15% to more than 30% depending on dose and population studied [44].

Patients frequently report a marked reduction in intrusive food-related thoughts and urges, a phenomenon colloquially described as the reduction of “food noise” [45]. While this effect facilitates adherence to energy restriction and supports weight loss, it also introduces a risk of insufficient protein, fiber, and fluid intake when meals are skipped or substantially reduced in size [46]. Early satiety and reduced appetite often lead to compressed eating windows and smaller portions, increasing the likelihood that patients fail to meet minimum intake thresholds necessary for lean mass preservation and metabolic stability [44,47].

From a nutrition management perspective, appetite suppression necessitates a shift toward structured intake prioritization [27]. Protein-forward meal construction, nutrient-dense food selection, and intentional meal timing become essential strategies to ensure adequate intake despite reduced hunger [27,48,49,50]. Rather than relying on intuitive eating cues alone, patients often benefit from a semi-structured eating pattern that ensures consistent protein and hydration intake across the day [51].

One of the primary mechanisms contributing to both weight loss and GI adverse events is delayed gastric emptying [40]. GLP-1RAs function in part as enterogastrones, slowing gastric motility and prolonging gastric distension following meals [29]. This prolongation enhances postprandial satiety but also increases the likelihood of nausea, fullness, reflux, and vomiting, particularly during dose escalation phases [40,52]. Clinical pharmacology studies confirm that GLP-1 receptor activation reduces gastric emptying rate and modulates vagal signaling, contributing to early satiety and reduced meal size [40].

The nutritional implications of pharmacologically slowed gastric emptying are substantial. Reduced gastric throughput effectively lowers functional meal capacity, meaning that larger or high-fat meals may provoke significant discomfort [40,53]. Observational and trial data consistently identify GI adverse events, especially nausea, vomiting, constipation, and reflux, as leading contributors to dose reduction or discontinuation [52]. A large-scale analysis involving 5442 cases further characterizes these GI profiles, noting that while severity may be influenced by age and body weight, the risk of these events typically follows an ‘early failure’ pattern that decreases over time as patients continue treatment [54]. A narrative review indicates that while GI side effects are the primary barrier to long-term therapy, these events are typically dose-dependent and manageable through individualized risk assessment and careful dose titration [19]. Many of these symptoms are highly sensitive to meal composition, portion size, and eating pace [55,56].

Accordingly, patients require explicit guidance on portioning logic and meal structure [55]. Smaller, more frequent meals; slower eating pace; careful titration of dietary fat; and attention to food texture can significantly improve tolerability [55,56]. Emphasis on nutrient density becomes critical because reduced gastric capacity limits total intake volume [57]. Ensuring that smaller meals deliver sufficient protein and overall dietary quality helps prevent unintended undernutrition while minimizing symptom burden [55].

Dual GIP/GLP-1RAs, such as tirzepatide, introduce additional metabolic effects that may influence nutritional priorities. In addition to GLP-1-mediated appetite suppression and delayed gastric emptying, GIP receptor activation appears to enhance adipocyte lipid handling, improve insulin sensitivity, and contribute to overall weight reduction through complementary mechanisms [58,59,60]. Data suggest that GIP signaling may support adipose tissue remodeling and metabolic flexibility, although its precise contribution to weight loss relative to GLP-1 remains an area of ongoing investigation [38,58].

Unlike GLP-1, GIP does not appear to exert a strong inhibitory effect on gastric emptying and may have neutral or modestly stimulatory effects on gastric motility in certain contexts [61]. A randomized crossover study in healthy volunteers distinguishes the incretin effects of these hormones, demonstrating that while both improve the insulinogenic index, GLP-1 specifically drives weight loss benefits through a unique combination of delayed gastric emptying and reduced hunger, effects that were not observed with GIP alone [61]. This distinction has led to hypotheses that dual agonists may demonstrate a somewhat different GI tolerability profile compared with high-dose GLP-1 monotherapy, although GI symptoms remain common across both classes [17,62]. For nutrition management, the central implication is that appetite suppression and reduced intake remain the dominant drivers of nutritional risk regardless of single or dual agonism [44].

From a nutrition-management perspective, the distinction between GLP-1RAs and dual GIP/GLP-1RAs is clinically relevant but should not be overstated. Dual incretin therapy may produce greater mean weight loss than many GLP-1 receptor agonist regimens, and GIP receptor activation may contribute additional effects on adipose tissue biology, insulin sensitivity, and metabolic regulation [63]. However, the practical nutrition priorities overlap substantially across both therapeutic classes because both can reduce appetite, lower total energy intake, alter meal size, and produce gastrointestinal symptoms during dose escalation. Therefore, nutrition care should be individualized according to the patient’s symptom profile, rate of weight loss, intake adequacy, body-composition risk, comorbidities, and treatment phase rather than assuming that GLP-1RAs and dual incretin therapies require entirely separate dietary algorithms [19,40,63].

Substantial reductions in spontaneous energy intake are consistently observed during incretin therapy [64]. Controlled feeding and free-living studies demonstrate decreases in caloric intake ranging from approximately 16% to nearly 40%, accompanied by shifts away from high-fat and highly processed foods [27,44]. While this energy reduction underpins weight loss efficacy, it also raises concerns regarding preservation of lean body mass and overall dietary adequacy [65]. Rapid or profound caloric reduction without structured protein intake and resistance training may predispose patients to disproportionate loss of fat-free mass, particularly in older adults or individuals with low baseline muscle reserves [27]. Randomized trial data in older adults with obesity demonstrate that resistance training maintains muscle strength and physical function during caloric restriction-induced weight loss, even when some lean mass is reduced, supporting the combined use of resistance exercise and adequate protein intake to mitigate sarcopenic risk [66].

Evidence from obesity and bariatric populations indicates that preservation of lean mass during weight loss requires sufficient protein intake distributed across meals and supported by resistance-based physical activity [67,68,69]. Without deliberate nutrition planning, medication-induced appetite suppression can lead to protein intakes below recommended thresholds, especially when patients consume only one or two small meals per day [61]. Fatigue, reduced physical activity, and diminished functional capacity may follow if energy and protein intake fall excessively [68].

Taken together, the pharmacological effects of GLP-1 receptor agonists and dual incretin therapies create a focused set of nutrition-management challenges: reduced appetite, lower meal capacity, altered food preferences, gastrointestinal symptoms, and potential inadequacy of protein, fluid, fiber, and micronutrient intake in susceptible patients [38,47,61]. These priorities are evidence-informed and mechanistically grounded, but direct trials demonstrating that specific nutrition strategies improve medication persistence, reduce adverse-event rates, or preserve fat-free mass during incretin therapy remain limited [27].

Key priorities include protein-forward meal structuring, attention to nutrient density, gradual fiber titration to support GI function, and proactive symptom management through portion control and meal timing strategies. By aligning nutrition care with pharmacologic mechanisms, clinicians may help patients anticipate reduced meal capacity, maintain adequate protein and fluid intake, and apply symptom-targeted dietary adjustments during dose escalation and active weight loss. Although these strategies are clinically plausible and supported by mechanistic rationale, expert consensus, and indirect evidence from the broader weight-loss and gastrointestinal literature, direct trials demonstrating improved persistence, reduced adverse-event rates, or superior body-composition outcomes during incretin therapy remain limited. The translation of incretin pharmacology into practical nutrition priorities is summarized in Figure 1, highlighting the mechanistic pathways through which these agents alter appetite, gastric motility, and dietary intake and the corresponding individualized nutrition considerations that may support tolerability, nutritional adequacy and long-term monitoring.

Before initiating GLP-1 receptor agonist or dual incretin therapy, a focused pre-treatment nutrition assessment is essential to identify baseline intake patterns that may influence tolerability, adherence, and body-composition outcomes during treatment [27,74,75]. Real-world evidence indicates that GI adverse effects, low dietary quality, and inadequate protein or fluid intake contribute to early discontinuation and suboptimal outcomes, underscoring the need to evaluate nutritional readiness before dose escalation begins [76]. Baseline assessment should therefore identify patients at risk for inadequate protein, fiber, fluid, and micronutrient intake during dose escalation [77,78]. This assessment is intended to guide anticipatory counseling and monitoring rather than to predict tolerability with certainty.

For routine clinical translation, pre-treatment assessment can be supported by brief, validated tools and simple checklists rather than lengthy dietary evaluations in all patients. Depending on local workflow and clinical resources, clinicians may combine a structured diet history with a brief diet-quality screener, such as the Rapid Eating Assessment for Participants–Short Version (REAP-S) or a Mediterranean diet adherence screener; a protein-intake checklist; a bowel-pattern assessment using stool frequency and stool form; a GI symptom checklist or validated symptom scale; a hydration checklist; and validated eating disorder screening tools such as the SCOFF questionnaire when clinically indicated [79,80,81,82]. These tools should support risk identification, counseling, and monitoring, rather than function as rigid eligibility criteria for pharmacotherapy.

Most individuals presenting for obesity pharmacotherapy demonstrate dietary patterns characterized by high energy density and low overall diet quality, often with irregular meal timing and reliance on ultra-processed foods [83]. Observational studies in obesity populations consistently show that poorer baseline diet quality and erratic meal patterns are associated with reduced adherence to weight-loss interventions and less favorable body-composition changes during caloric restriction. A secondary analysis of a large, randomized weight-loss trial in generally healthy adults demonstrated that participants who improved both diet quality and adherence to macronutrient targets achieved significantly greater reductions in BMI over 12 months than those with poorer diet quality and adherence, highlighting the combined importance of dietary quality and consistency for successful weight loss [73]. Similarly, longitudinal cohort data from the MRC National Survey of Health and Development showed that healthier dietary pattern scores across midlife were associated with lower fat mass and more favorable adiposity distribution in later adulthood, supporting the role of sustained diet quality in shaping long-term body composition [84]. Assessing baseline dietary pattern, whether through brief validated tools such as Mediterranean diet adherence scores or through structured diet history, can help identify patients whose intake is dominated by energy-dense, low-protein foods that may be poorly tolerated once appetite declines [72,85,86]. Particular attention should be paid to meal timing and frequency, as prolonged fasting periods followed by large meals can exacerbate nausea, reflux, and early satiety when gastric emptying is pharmacologically delayed [27,87,88,89]. Establishing a predictable meal structure prior to treatment initiation improves tolerance and supports more consistent nutrient intake once appetite suppression occurs [33,71].

Protein, fluid, and fiber intake patterns warrant specific assessment given their central role in maintaining nutritional adequacy and GI function during incretin therapy [78,90]. Clinical studies demonstrate that GLP-1-based treatments significantly reduce spontaneous energy intake, which can inadvertently lower protein consumption below levels required to preserve lean body mass during weight loss [91]. Inadequate protein intake during energy restriction has been associated with greater fat-free mass loss and functional decline, particularly in older adults and individuals with sarcopenic obesity [92]. In a 20-week randomized weight-loss trial in postmenopausal women aged 50–70 years, higher dietary protein intake during caloric restriction was significantly associated with reduced total and appendicular lean mass loss, even after adjustment for intervention group and body size, supporting the importance of adequate protein intake to mitigate adverse body-composition changes during weight reduction [93]. Similarly, insufficient fluid intake is a common but underrecognized contributor to treatment-related nausea, fatigue, and constipation, while low baseline fiber intake increases the likelihood of constipation once gastric emptying slows and food volume decreases [56]. Expert consensus on nutrition management for GLP-1 therapy emphasizes the importance of adequate macronutrient and fluid intake alongside resistance training to preserve muscle and mitigate adverse effects such as nausea and dehydration-related complications [70]. Evaluating typical daily protein intake and distribution, hydration habits, and fiber exposure before medication initiation may support individualized counseling on protein prioritization, scheduled fluid intake, and gradual fiber titration, while recognizing that direct evidence linking these pre-treatment adjustments to reduced intolerance remains limited.

Micronutrient adequacy should also be considered during baseline assessment and follow-up, particularly because appetite suppression, early satiety, reduced dietary variety, and persistent gastrointestinal symptoms may reduce overall micronutrient intake during therapy [94]. Current evidence does not support universal micronutrient supplementation for all patients receiving GLP-1 receptor agonist or dual incretin therapy; however, individualized monitoring may be appropriate in patients with low baseline dietary quality, prolonged nausea or vomiting, diarrhea, restrictive eating patterns, older age, prior metabolic or bariatric surgery, chronic kidney disease, or other conditions associated with nutritional vulnerability. When clinically indicated, assessment may include dietary review and targeted laboratory evaluation of nutrients such as vitamin D, vitamin B12, iron status, folate, calcium, magnesium, and electrolytes, with supplementation guided by documented deficiency, inadequate intake, or established clinical indication rather than routine use [28,95].

Pre-existing GI symptoms are clinically relevant for anticipatory counseling during GLP-1RA or dual incretin therapy. Patients with baseline constipation, reflux, irritable bowel symptoms, rapid eating patterns, large evening meals, or high dietary fat intake may be more likely to experience symptom exacerbation during dose escalation [56]. GI adverse events are consistently reported as common reasons for dose adjustment, delayed escalation, or discontinuation in clinical and real-world settings [20,96,97]. Screening for bowel habits, stool frequency, habitual fat intake, eating speed, and typical meal size provides clinically actionable information [98,99]. Patients who routinely consume large evening meals or eat rapidly may benefit from anticipatory counseling on portion reduction, slower eating pace, and earlier meal timing to mitigate nausea and reflux during dose escalation [98,100,101,102]. Addressing constipation risk through hydration optimization, gradual fiber introduction, and physical activity recommendations prior to treatment initiation could improve early tolerability.

Although incretin therapies are being investigated for their potential effects on binge-eating symptoms, their potent appetite-suppressing effects may also mask or exacerbate restrictive eating patterns in vulnerable patients [103]. A recent systematic review of GLP-1RAs in binge eating disorder and bulimia nervosa reported reductions in binge-eating frequency and related psychopathology in small pilot studies, while emphasizing the need for larger randomized trials to establish efficacy and safety [104]. Therefore, GLP-1RAs and dual incretin therapies should not be presented as established treatments for eating disorders, and appetite suppression should not be equated with recovery, normalization of eating behavior, or adequate nutritional intake [104,105].

Screening for a history of disordered eating, including binge eating, chronic restrictive dieting, or significant weight suppression, is therefore appropriate when clinically indicated [106,107]. The purpose of screening is risk identification and care planning, not automatic exclusion from obesity pharmacotherapy. Brief validated tools such as the SCOFF questionnaire or Eating Disorder Diagnostic Scale can be incorporated into pre-treatment evaluation to identify patients who may require closer monitoring or multidisciplinary support [108,109,110]. In addition to brief screening instruments, multidimensional progress-monitoring tools have been developed and validated to track eating disorder symptoms and related behavioral and psychological domains over time, supporting structured identification and follow-up of patients at higher risk [111]. Importantly, rapid reductions in appetite and food preoccupation during therapy may be perceived as therapeutic success, even when total intake becomes nutritionally inadequate [27,44]. Patients with active eating disorder symptoms, significant restrictive tendencies, recurrent binge eating, purging behaviors, or severe weight/shape concerns should be managed with multidisciplinary oversight, ideally involving obesity medicine, nutrition, and mental health professionals with eating disorder expertise [103,105,106]. Structured guidance on minimum intake targets, protein prioritization, regular meal patterns, and symptom monitoring may help ensure that pharmacotherapy supports nutritional adequacy and sustainable weight management without reinforcing maladaptive restriction.

For pragmatic implementation, patients may be categorized into lower or higher nutritional risk before treatment initiation. Lower-risk patients may have regular meal patterns, adequate baseline protein and fluid intake, minimal GI symptoms, preserved muscle strength, no major restrictive or binge-eating risk, and reliable follow-up access. Higher-risk features include low baseline protein intake, poor diet quality, chronic constipation or reflux, low fluid intake, older age, sarcopenic obesity or low muscle strength, prior metabolic or bariatric surgery, chronic kidney disease, restrictive or disordered eating risk, persistent vomiting or diarrhea, and anticipated barriers to follow-up. Patients with higher nutritional risk may benefit from earlier dietitian involvement, closer monitoring during dose escalation, and more individualized protein, hydration, fiber, micronutrient, symptom-management, and physical-activity planning. A structured framework for pre-treatment nutrition assessment and targeted clinical action is summarized in Table 1.

While Table 1 summarizes key domains for pre-treatment nutrition assessment, nutrition support during incretin therapy extends beyond the initial evaluation phase. As treatment progresses through dose escalation, active weight loss, and long-term maintenance, different nutrition-related risks and priorities emerge. To contextualize these phases within a clinical workflow, Figure 2 illustrates an operational framework for integrating nutrition assessment, risk identification, evidence-informed strategies, and ongoing monitoring throughout the course of incretin-based therapy.

GI adverse events are the most frequently reported side effects of GLP-1RAs and dual incretin therapies and are clinically relevant contributors to dose-escalation failure and early treatment discontinuation [26]. Across major obesity trials, nausea, vomiting, diarrhea, and constipation are commonly reported, with nausea often affecting approximately 20–40% of treated participants depending on agent, dose, population, and ascertainment method [6,7,16,121]. These symptoms are typically most pronounced during dose escalation and are dose-dependent [6,19]. Because many symptoms are meal-related, dietary and behavioral strategies may help reduce symptom burden in selected patients, although direct evidence that these strategies improve long-term adherence remains limited [32,101]. Accordingly, the approaches in this section should be interpreted as pragmatic, individualized clinical considerations rather than validated symptom-management algorithms.

In practice, symptom-directed nutrition management can be approached stepwise. First, clinicians should assess symptom severity, hydration status, oral intake, bowel pattern, recent dose escalation, and alarm features such as persistent vomiting, severe abdominal pain, progressive distension, dehydration, or inability to maintain intake. Second, meal pattern and exposure to common triggers should be reviewed, including large portions, rapid eating, high-fat meals, late evening meals, carbonated beverages, alcohol, sugar alcohols, low fluid intake, and abrupt fiber increases. Third, first-line dietary adjustments should focus on smaller structured meals, slower eating pace, protein prioritization in tolerable portions, moderation of dietary fat, scheduled fluid intake between meals, and gradual fiber titration according to symptoms. Fourth, symptom-specific strategies can then be applied for nausea, reflux, constipation, diarrhea, or bloating, as summarized in Table 2. Finally, persistent, severe, or progressive symptoms should prompt medical reassessment, consideration of dose-escalation delay or dose adjustment, and evaluation for alternative diagnoses or complications rather than relying on dietary modification alone [40,56,121].

Brief patient-centered counseling messages may improve translation of symptom-targeted strategies into daily practice. Clinicians can explain early satiety by advising patients that “fullness may arrive earlier than expected, so the goal is to stop at comfortable fullness rather than finish the plate.” Portion control can be framed as “start with a smaller portion, eat slowly, and pause midway before deciding whether more food is needed.” Eating pace can be addressed by encouraging patients to take smaller bites, chew thoroughly, and avoid eating while distracted. For hydration, patients may be advised to sip fluids between meals rather than drinking large volumes with meals if fullness or reflux occurs. For constipation or bloating, fiber should be increased gradually rather than abruptly. These messages should be individualized according to symptom severity, cultural food practices, food access, comorbidities, and eating disorder risk [40,56]. These counseling points are intended as practical communication tools and should not be interpreted as evidence that dietary counseling alone prevents gastrointestinal adverse events or medication discontinuation.

Because randomized trials have not yet established symptom-directed dietary algorithms specifically for incretin-treated populations, the strategies discussed below should be interpreted as pragmatic, individualized clinical considerations. Their purpose is to help clinicians identify modifiable meal-related triggers, maintain hydration and nutrient intake, and determine when symptoms require medical reassessment rather than dietary adjustment alone.

Nausea is the most common adverse event during incretin therapy and is strongly associated with delayed gastric emptying and heightened gastric distension signaling [40]. Symptoms are often most severe in the first days following injection or after dose increases [19]. In the STEP randomized trials of semaglutide for obesity, nausea and vomiting were the most frequently reported gastrointestinal adverse events and were typically transient, mild-to-moderate in severity, and occurred most often during treatment initiation and dose escalation [16,121,122]. Continuing to eat beyond the first sensation of fullness can precipitate nausea and vomiting due to reduced gastric clearance and prolonged gastric retention [123].

Nutritional management should focus on volume control, pacing, and food composition. Patients benefit from explicit guidance to stop eating at early satiety cues and to prioritize smaller, structured meals [27,72]. Lower-fat meals are generally better tolerated, as dietary fat further slows gastric emptying and may exacerbate symptoms [124]. During symptomatic periods, lower-fat, more easily digested carbohydrate and meal compositions may be better tolerated than high-fat, heavily seasoned foods, as clinical guidance suggests modifying dietary fat and food consistency to minimize nausea and improve gastrointestinal tolerability during GLP-1 therapy [27,125]. Adequate hydration is also critical, as reduced fluid intake during appetite suppression may exacerbate nausea, fatigue, constipation, and in vulnerable patients may contribute to dehydration-related renal complications [126,127]. Small, frequent sips of fluids between meals are often better tolerated [56]. Temperature and sensory modifications may further reduce symptoms, as cold or room-temperature foods are frequently perceived as less nauseating than hot, aromatic dishes [27,56].

Constipation is common during GLP-1-based therapy and may persist for longer than nausea [16,40]. Slowed gastric emptying and reduced overall food intake decrease luminal bulk, while reduced fluid intake further impairs stool transit [40,128]. Additionally, the marked reduction in total food intake commonly observed during incretin therapy may further reduce stool bulk and intestinal motility, contributing to constipation if fiber and fluid intake are not intentionally maintained. Observational data and trial reports consistently identify constipation as a frequent reason for patient discomfort and dose adjustment. In the STEP pooled analysis of phase III semaglutide trials, constipation was among the most frequently reported gastrointestinal adverse events alongside nausea and vomiting, highlighting its clinical significance during therapy [121]. Similarly, in the STEP 5 semaglutide randomized trial, constipation was consistently observed in the semaglutide treatment arm as a common adverse event, supporting the need for proactive symptom management [129].

Data indicate that proactive management may be better than a reactive approach. Gradual fiber titration is preferred over abrupt increases, as rapid escalation can exacerbate bloating and abdominal discomfort [98]. Bellini et al. [98] recommend that enrichment of the diet with fiber should be slow and gradual to avoid or reduce disturbances such as bloating, flatulence, and intestinal cramps, particularly in the context of constipation management. A systematic review and meta-analysis of randomized controlled trials found that, while fiber improves stool frequency and consistency, higher doses (e.g., >10 g/day) and longer treatment durations are necessary for optimal effect, and adverse effects such as flatulence and bloating are more common with higher fiber doses [130]. A total fiber intake target consistent with general dietary evidence-informed clinical considerations (approximately 25–35 g/day, individualized to tolerance) is reasonable, though baseline intake should guide progression [131]. Soluble fiber sources, including oats, apples, and psyllium, may improve stool consistency and promote transit. Psyllium is particularly useful due to its gel-forming properties and minimal fermentation compared with some other fibers, which may reduce bloating while normalizing stool form [132]. Adequate hydration and regular physical activity should be emphasized alongside fiber adjustments to support bowel motility [130,131]. In patients with persistent constipation despite adequate hydration and gradual fiber titration, magnesium-based osmotic agents may be considered as adjunctive therapy to improve stool water content and intestinal motility [133].

Although less common than constipation, diarrhea and bloating can occur, particularly during early treatment or rapid dose escalation. These symptoms may reflect alterations in intestinal transit, changes in bile acid handling, or increased sensitivity to dietary fat [19,134]. High-fat meals, spicy foods, sugar alcohols, and excessive caffeine may exacerbate gastrointestinal symptoms in susceptible individuals, as these dietary factors are known to worsen dyspepsia, bloating, and diarrhea through effects on gastric motility, visceral sensitivity, and osmotic load [27,135,136]. Nutritional strategies focus on reducing luminal irritants and stabilizing stool consistency [32,77,78]. Temporarily emphasizing soluble fiber (e.g., bananas, rice, applesauce, oats) may help improve stool form [130,131]. Limiting high-fat and greasy foods during symptomatic periods is advisable, as is reducing intake of sugar alcohol-containing products [48]. Although most gastrointestinal adverse effects are mild and self-limited, persistent or clinically significant symptoms may require dose adjustment or medical management, particularly when oral intake or hydration is compromised [16,56,90,137]. A summary of symptom-specific mechanisms and targeted nutrition strategies to improve tolerability is provided in Table 2.

The substantial weight loss induced by GLP-1 receptor agonists and dual incretin therapies raises an important body-composition consideration: how to maximize fat-mass reduction while limiting excessive loss of fat-free mass [91]. Across pharmacologic weight-loss trials, reductions in fat-free mass typically account for approximately 20–40% of total weight lost, a proportion comparable to other hypocaloric interventions [91,138]. Available incretin-specific body-composition data suggest that weight loss with semaglutide and tirzepatide is driven predominantly by reductions in fat mass, although lean mass or fat-free mass also declines as part of total weight loss [16,139]. Given that excessive lean mass loss may reduce resting energy expenditure and impair physical function, clinical guidance commonly includes the active management of the rate of weight loss and the quality of intake. Obesity evidence-informed clinical considerations commonly recommend a moderate energy deficit (≈500–750 kcal/day) to support clinically meaningful weight loss while reducing the risk of disproportionate fat-free mass losses that are more likely with aggressive caloric restriction [140,141,142].

Appetite suppression and early satiety increase the risk of inadequate protein intake unless proactively addressed, particularly as dietary variety and total oral intake often decline during GLP-1RA dose escalation [44,143]. A recent clinical nutrition perspective highlights that early satiety and reduced dietary variety during GLP-1RA therapy often result in substantially lower oral intake, which can lead to inadequate nutrient intake and necessitates careful dietary planning [95]. However, randomized trials have not yet tested protein dose–response strategies specifically in patients receiving GLP-1RAs or dual GIP/GLP-1RAs. Accordingly, protein targets during incretin therapy should be interpreted as extrapolated from broader obesity, caloric restriction, aging, sarcopenia, and exercise-nutrition literature rather than as incretin-specific evidence-based thresholds [144,145].

Protein intake is therefore central to nutrition management during incretin therapy. Evidence from obesity and caloric restriction trials supports protein intakes in the range of approximately 1.2–1.6 g/kg/day (adjusted for age, renal function, and comorbidities) support fat-free mass retention and reduce the risk of inadequate intake during active weight reduction [146,147,148]. Individuals with sarcopenic obesity, low baseline muscle mass, or impaired strength may benefit from targeting the upper end of this range, combined with early initiation of resistance training, whereas metabolically healthy individuals with preserved muscle mass may remain closer to the lower end of this spectrum provided adequate mechanical stimulus is present [112,148,149,150]. These targets should be individualized according to age, renal function, baseline muscle mass, comorbidities, dietary tolerance, and treatment phase; in patients with chronic kidney disease or other conditions requiring protein restriction, higher-protein targets should not be applied without individualized clinical and dietetic assessment [112,148,149,150].

Importantly, muscle protein synthesis is optimized when protein intake is distributed across meals rather than consumed in a single large bolus [151]. Intakes of roughly 25–35 g of high-quality protein per eating occasion are generally sufficient to maximally stimulate muscle protein synthesis in most adults, particularly when leucine-rich sources are included [152]. This anabolic response is closely linked to a per-meal leucine threshold of approximately 2.5–3.0 g, typically achieved with ~25–35 g of high-quality protein from sources such as whey, dairy, eggs, lean poultry, fish, or soy. Suboptimal protein quality or highly uneven daily distribution may blunt muscle protein synthesis even when total daily protein intake appears adequate [153,154,155]. However, the per-meal leucine threshold has not been specifically validated as a clinical target during incretin-based obesity pharmacotherapy; therefore, leucine should be framed as a marker of high-quality protein intake rather than as a stand-alone supplementation requirement for all patients [153,154,155].

Because appetite is often markedly reduced, clinical practice models frequently emphasize prioritizing protein consumption at the beginning of meals to help ensure adequate intake before early satiety limits consumption [156]. This “protein-first” strategy is especially relevant in individuals consuming smaller meals or fewer daily eating occasions [156]. Nevertheless, it should be implemented flexibly and without reinforcing restrictive eating patterns, particularly in patients with a history of disordered eating or very low intake.

Practical meal-planning guidance may include anchoring each eating occasion around a high-quality protein source (e.g., Greek yogurt, cottage cheese, eggs, tofu/tempeh, fish, or poultry), followed by fiber-containing carbohydrates and cardioprotective fats in modest portions to maintain tolerability [157,158]. Randomized controlled trials of higher-protein diets during caloric restriction consistently demonstrate greater retention of fat-free mass compared with lower-protein diets, and meta-analyses indicate that protein supplementation combined with resistance training confers additive benefits for muscle mass and strength preservation, particularly in older adults and those at risk for sarcopenia [147,159]. These data support the biological plausibility and clinical rationale for protein prioritization during incretin therapy, but they remain largely indirect for GLP-1RA- or dual incretin-treated populations [144,160].

Meal timing may also contribute to anabolic signaling. Protein ingestion in the hours surrounding resistance training can enhance post-exercise muscle protein synthesis and lean mass adaptations, particularly in older adults, although the precise “anabolic window” is broad and total daily protein intake often exerts a stronger influence on long-term hypertrophy outcomes [161,162]. Caution is warranted with unsupervised time-restricted eating approaches, as shortened eating windows may inadvertently reduce total protein intake unless carefully structured [163]. Although this review focuses primarily on macronutrient strategies, clinicians should also consider adequate omega-3 fatty acid intake, and diets rich in antioxidant-containing fruits and vegetables may support overall musculoskeletal health within a Mediterranean-style framework [163,164,165]. Furthermore, emerging evidence suggests that, beyond total protein intake, protein quality, particularly leucine content, as well as adequate vitamin D status may contribute to the preservation of fat-free mass and muscle strength during weight loss [145]. Accordingly, supplementation strategies including branched-chain amino acids and vitamin D may be considered in selected patients, particularly in those at risk of sarcopenia or with documented deficiency. However, routine branched-chain amino acid or vitamin D supplementation should not be implied for all patients receiving incretin therapy; supplementation should be individualized according to dietary intake, deficiency status, sarcopenia risk, renal function, and clinical context.

Resistance training provides the complementary mechanical stimulus needed to support muscle strength, physical function, and fat-free mass retention during weight loss [164]. Randomized trials in hypocaloric states consistently demonstrate that resistance exercise performed two to three times per week attenuates lean mass loss, preserves fat-free mass, and improves functional outcomes during weight reduction. Trials combining caloric restriction with structured resistance training show greater preservation of lean mass and improvements in strength and mobility compared with diet-only interventions [66,165]. A meta-analysis of 49 randomized controlled trials involving prolonged resistance exercise training found that dietary protein supplementation significantly enhanced resistance training-induced increases in fat-free mass (mean difference 0.30 kg, 95% CI 0.09 to 0.52) and one-repetition-maximum strength (mean difference 2.49 kg, 95% CI 0.64 to 4.33) compared with resistance training alone, with diminishing additional benefit above ~1.6 g/kg/day total protein intake [145]. Another systematic review and meta-analysis in community-dwelling older adults with sarcopenia reported that combining protein supplementation with resistance exercise significantly increased muscle mass (standardized mean difference [SMD] 0.95, 95% CI 0.13–1.78) and muscle strength (SMD 0.32, 95% CI 0.08–0.56) compared with control conditions, supporting additive effects of nutritional and exercise interventions in this population [166].

These data strongly support the biological rationale for combining adequate protein intake with resistance training during weight reduction. However, most evidence comes from caloric restriction, aging, sarcopenia, and exercise-nutrition studies rather than randomized trials specifically conducted in GLP-1 receptor agonist or dual incretin-treated populations [66,145,165,167]. Accordingly, resistance training should be framed as a strongly evidence-informed extrapolation for patients receiving incretin therapy, rather than as an intervention already proven to improve body-composition outcomes in this specific pharmacologic context.

Pharmacotherapy can reduce appetite and energy intake, but it does not provide the mechanical loading stimulus required to maintain or improve muscle strength and functional capacity [166]. Aerobic exercise remains valuable for cardiometabolic health; however, resistance training appears central when the goal is supporting strength, physical function, and attenuation of excessive fat-free mass loss [114,168]. Concurrent training programs can be effective when appropriately balanced, avoiding excessive endurance volume that may compromise strength adaptations [169,170]. In the context of incretin therapy, the combination of sufficient protein intake and structured resistance training represents a clinically plausible and evidence-informed strategy to support healthier body composition and functional capacity during active weight reduction, while recognizing that direct incretin-specific exercise trials remain limited.

While incretin-based pharmacotherapy reduces total energy intake across a range of dietary patterns, dietary quality remains clinically relevant for cardiometabolic health, gastrointestinal tolerance, nutritional adequacy, and long-term sustainability [27,56,120]. Rather than prescribing rigid macronutrient ratios, evidence supports emphasizing dietary patterns that are nutrient-dense, digestively tolerable, and sustainable beyond the active pharmacotherapy phase [171,172].

A Mediterranean-style dietary pattern provides a strong evidence base for cardiometabolic benefit and long-term adherence [173,174,175,176,177]. Characterized by abundant vegetables, fruits, legumes, whole grains, fish, olive oil, and moderate dairy intake, this pattern aligns well with the reduced appetite and smaller meal volumes typical of incretin therapy [78,178,179]. A higher-protein Mediterranean variant may be particularly advantageous during active weight loss to support lean mass preservation while maintaining cardiovascular risk reduction [180,181].

Gut microbiota may represent an additional mechanistic link between dietary pattern quality, metabolic health, and inter-individual variability in response to incretin-based therapies. GLP-1RAs and changes in diet or weight loss may influence gut microbial composition, while microbial metabolites such as short-chain fatty acids and bile-acid derivatives may modulate endogenous incretin signaling [182]. However, most evidence remains mechanistic, preclinical, or observational, and causality in humans is not established. Therefore, microbiota-directed strategies should not currently be presented as specific clinical tools to enhance GLP-1 receptor agonist or dual incretin response. Instead, clinicians should emphasize dietary patterns already supported for cardiometabolic health and gastrointestinal function, including adequate fiber, legumes, fruits, vegetables, whole grains, and minimally processed foods, while recognizing microbiota modulation as an emerging research area [182,183].

Lower-carbohydrate approaches, including moderate carbohydrate restriction (<130 g/day), may improve glycemic control in individuals with type 2 diabetes and can be compatible with incretin therapy [184]. However, excessively restrictive carbohydrate intake may inadvertently reduce fiber consumption and increase the risk of constipation in the setting of delayed gastric emptying [98,99]. Careful attention to non-starchy vegetables, legumes, and other fiber-containing foods remains important.

Hybrid or adaptive dietary approaches, including ketogenic-Mediterranean patterns, have been proposed to counter reductions in energy expenditure during rapid weight loss. Controlled feeding and intervention studies suggest that nutritional ketosis or lower-carbohydrate diets may attenuate declines in resting metabolic rate or modestly increase energy expenditure during weight-loss phases, although findings remain heterogeneous and context dependent [185,186,187,188,189,190,191,192]. While short-term metabolic effects have been described in tightly controlled feeding studies, long-term comparative data in patients receiving incretin therapy remain limited. Accordingly, such approaches should be individualized and monitored to ensure adequate protein, fiber, and overall dietary quality.

Importantly, incretin therapy frequently reduces hedonic drive for ultra-processed and energy-dense foods, creating an opportunity to reshape long-standing dietary habits [193,194]. Evidence suggests that clinicians should leverage this period of reduced “food noise” to establish structured meal patterns and high-quality dietary practices that can be sustained if medication is tapered or discontinued [51,195]. Dietary strategies adopted during therapy should therefore prioritize sustainability and metabolic resilience, forming the foundation for long-term weight maintenance rather than serving as a temporary adjunct to pharmacologic appetite suppression. Long-term weight-loss research consistently demonstrates that durable outcomes are most strongly associated with sustained dietary adherence, high-quality eating patterns, and ongoing behavioral support rather than short-term macronutrient manipulation alone [195,196]. Studies further show that individuals who maintain weight loss over time are more likely to adhere to structured, nutrient-dense dietary patterns and consistent eating behaviors, underscoring the importance of establishing sustainable nutrition strategies during active treatment phases [197]. To support clinical translation, Table 3 summarizes key nutrition priorities during incretin-based therapy, integrating protein targets, fiber and hydration goals, meal structure, and dietary pattern recommendations.

Planning for weight maintenance and potential medication discontinuation is a critical yet often underdeveloped component of incretin-based obesity treatment [78]. Randomized withdrawal trials consistently demonstrate that cessation of GLP-1 or dual incretin therapy is followed by partial or substantial weight regain in many patients. In the STEP 1 extension, participants who discontinued semaglutide regained a mean of 11.6 percentage points of lost weight during the off-treatment extension, corresponding to approximately two-thirds of the prior weight loss. In SURMOUNT-4, withdrawal of tirzepatide after an initial treatment period led to substantial regain, whereas continued therapy maintained and augmented weight reduction [5,137]. In analyses from the STEP semaglutide program, participants regained a significant proportion of lost weight after treatment withdrawal compared with placebo, and in the SURMOUNT-4 tirzepatide withdrawal trial, those discontinuing therapy experienced marked recoupment of body weight that contrasted with continued weight maintenance on active treatment. Meta-analytic evidence further confirms that stopping GLP-1RA or dual agonist therapy results in rapid rebound of weight loss and attenuation of metabolic benefit [3,137,207]. These findings reinforce the chronic nature of obesity and highlight the need for structured long-term nutrition and behavioral strategies, regardless of whether pharmacotherapy is continued indefinitely or eventually tapered.

Although evidence remains limited regarding optimal discontinuation protocols, gradual dose reduction is commonly used in clinical practice to mitigate abrupt increases in appetite and caloric intake [208]. When gradual dose reduction is used in clinical practice, it may help patients adapt to returning hunger cues while reinforcing structured eating patterns and protein prioritization [27,77]. Some clinicians have also explored extended dosing intervals or lower “maintenance” doses once target weight is achieved; however, robust comparative trials evaluating these approaches are lacking [209]. A recent modeling analysis explored alternative dosing regimens of GLP-1RAs and suggested that reducing dosing frequency (e.g., from once weekly to once every two weeks) could maintain a large proportion (≈75%) of weight loss, but these findings should be considered hypothesis-generating rather than evidence of an established maintenance protocol [210]. Until stronger evidence emerges, discontinuation planning should emphasize reinforcement of sustainable dietary patterns, adequate protein intake, and continued physical activity.

Structured physical activity plays an important role in weight-loss maintenance following pharmacotherapy [64,68]. Exercise interventions after weight reduction have been shown to improve appetite regulation, support energy expenditure, and attenuate weight regain across obesity populations [68]. Emerging evidence also suggests that regular exercise may enhance endogenous GLP-1 responses and postprandial satiety signaling, providing a physiologic complement to pharmacologic therapy [211,212]. Establishing consistent resistance and aerobic exercise routines during active treatment may therefore help buffer against rebound hyperphagia if medication is reduced or discontinued [64].

The rapid expansion of incretin-based pharmacotherapy has created new demands on clinical workflows, requiring structured, multidisciplinary approaches to ensure safe and effective long-term management. Programs that integrate obesity medicine clinicians, registered dietitians, and behavioral health professionals are best positioned to address the physiological, nutritional, and behavioral determinants of treatment success [95,229]. Nutrition support is particularly critical during early dose escalation and during transitions to maintenance or discontinuation phases [27,77,90].

Frequent follow-up during the initiation phase improves tolerability and adherence. In the absence of comparative trials defining optimal follow-up intensity during incretin-based obesity pharmacotherapy, visit frequency should be individualized according to dose-escalation phase, symptom burden, nutritional risk, comorbidities, and access to care [208,209]. Once a stable maintenance dose is achieved, follow-up intervals can typically be extended to every three to six months, with interim contact as needed for symptom management or weight changes [230]. Telehealth delivery models, asynchronous nutrition support, and remote monitoring tools may improve access and continuity of care, but their effectiveness specifically among patients receiving GLP-1 receptor agonist or dual incretin therapy requires further evaluation. These approaches should therefore be viewed as implementation strategies with emerging relevance rather than established consensus standards [27,231,232,233].

Remote patient monitoring tools may further enhance care delivery. Connected scales and digital monitoring platforms allow clinicians to track weight trajectories in real time, improving engagement and retention while enabling early identification of clinically meaningful changes that may signal excessive caloric restriction, dehydration, or emerging nonadherence. Studies of digital weight-management programs show that provision of connected scales and remote monitoring increases frequency of self-weighing, improves retention, and facilitates timely clinical feedback, all of which are associated with greater likelihood of achieving clinically significant weight loss and sustaining behavioral adherence [234]. Early identification of unintended rapid weight loss or regain enables timely dietary counseling, adjustment of medication dosing, or reinforcement of behavioral strategies [235,236]. It is important to recognize that not all patients have access to or are comfortable with digital technologies (barriers including limited digital literacy, connectivity, or device availability can impede engagement) and low-tech alternatives such as paper food logs, telephone check-ins, and manual self-monitoring remain valuable strategies for supporting adherence and dietary behavior change in these populations [237,238].

Emerging practice models commonly use more frequent contact during early dose escalation to address gastrointestinal symptoms, reinforce protein and hydration targets, and identify inadequate intake or rapid unintended weight loss. Once patients are clinically stable, follow-up intervals may be extended, although the optimal schedule remains uncertain. The practical application of these principles is summarized in the clinical decision algorithm presented in Figure 3.

The following take-home messages summarize pragmatic clinical considerations derived from direct incretin evidence where available and from the indirect nutrition, gastrointestinal, body-composition, and expert-consensus literature where direct evidence is lacking. First, nutrition care should begin before or at the initiation of incretin-based therapy, because appetite suppression, early satiety, and gastrointestinal symptoms can reduce meal size, dietary variety, protein intake, fluid intake, and fiber tolerance. Second, protein, hydration, fiber, and meal structure should be individualized during dose escalation, with particular attention to patients with low baseline intake, gastrointestinal symptoms, older age, sarcopenic obesity, chronic kidney disease, prior metabolic or bariatric surgery, or restrictive/disordered eating risk. Third, gastrointestinal symptoms are often meal-related and may improve with smaller portions, slower eating pace, moderate dietary fat, scheduled hydration, and gradual fiber titration; however, persistent or severe symptoms require medical reassessment. Fourth, protein and resistance-training strategies are clinically relevant for body-composition monitoring, but their targets are largely extrapolated from the broader weight-loss, aging, sarcopenia, and exercise-nutrition literature rather than incretin-specific nutrition trials. Fifth, maintenance planning should begin during active weight loss, particularly for patients at risk of treatment interruption, because medication discontinuation is commonly followed by partial or substantial weight regain.